ArticleInternational journal of nanomedicine2026
Differential Proteomic Landscape of Plasma Neuron-Derived Extracellular Vesicles in Parkinson's Disease with and without RBD: A Pilot Investigation.
Article in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parkinson's disease (PD) is clinically heterogeneous, and the presence of rapid eye movement sleep behavior disorder (RBD) defines a distinct and aggressive subtype. There is an urgent need for molecular biomarkers to understand and identify these subtypes. Neuron-derived extracellular vesicles (nEVs) provide a window into brain pathology. Methods: In this pilot study, we isolated plasma nEVs via L1CAM immunocapture from 28 subjects (PD-RBD, PD-noRBD, and controls). Proteomic analysis was performed using data-independent acquisition mass spectrometry (DIA-MS). Results: We quantified 1354 proteins. Comparative analysis revealed 239 differentially expressed proteins (DEPs) between PD-RBD and PD-noRBD. PD-RBD patients exhibited significantly higher levels of α-synuclein (SNCA) and showed pronounced enrichment in extracellular matrix remodeling (eg, NRGN, ELAV3) pathways. In contrast, PD-noRBD was characterized by dysregulated lipid metabolism (eg, APOE, CETP) and systemic inflammation. Specific DEPs correlated with motor severity, autonomic dysfunction, and brain iron deposition. Conclusion: This pilot study reveals distinct proteomic profiles between the plasma nEVs of PD-RBD and PD-noRBD, suggesting divergent pathophysiological processes involving structural/extracellular matrix remodeling versus systemic metabolic-inflammatory pathways. These findings provide a prioritized panel of candidate nEV biomarkers for subtype-specific stratification in PD, which warrant further large-scale clinical and functional validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.